Sign in

CIK 0001357874

  • Non-accelerated filer
  • Smaller reporting company

PRECISION BIOSCIENCES INC

Sign in to watch
Ticker
DTIL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
May 21
Incorporated
DE
Entity type
Operating
Phone
+1 919-314-5512
Business address
302 EAST PETTIGREW STREET, SUITE A-100, DURHAM, NC, 27701
  1. 4 Option exercise Director acquired 21,000 shares (option exercise)
  2. 4 Planned sale President and CEO sold 20,559 shares at $3.84 ($78,947)
  3. 4 Planned sale Chief Financial Officer sold 8,149 shares at $3.84 ($31,292)
  4. 4 Planned sale General Counsel and Secretary sold 4,925 shares at $3.84 ($18,912)
  5. 4 Planned sale Chief Research Officer sold 4,925 shares at $3.84 ($18,912)
  6. 4 Planned sale President and CEO sold 34,799 shares at $4.17 ($145,112)
  7. 4 Planned sale General Counsel and Secretary sold 8,854 shares at $4.03 ($35,682)
  8. 4 Planned sale Chief Financial Officer sold 15,213 shares at $4.03 ($61,308)
  9. 4 Planned sale Chief Research Officer sold 10,200 shares at $4.03 ($41,106)
  10. 4 Open-market buy Director bought 3,000 shares at $4.72 ($14,160)
  11. 4 Open-market buy Director bought 2,700 shares at $4.70 ($12,690)
  12. 4 Open-market buy Director bought 1,381 shares at $4.97 ($6,864)
  13. 4 Planned sale Chief Financial Officer sold 1,303 shares at $6.49 ($8,456)
  14. 4 Planned sale General Counsel and Secretary sold 665 shares at $6.49 ($4,316)
  15. 4 Planned sale President and CEO sold 3,409 shares at $6.49 ($22,124)
  16. 4 Open-market buy Director bought 2,700 shares at $4.97 ($13,419)
  17. 4 Open-market buy Director bought 1,400 shares at $4.89 ($6,846)
  18. 4 Planned sale Chief Financial Officer sold 14,827 shares at $4.26 ($63,163)
  19. 4 Open-market buy Director bought 1,682 shares at $4.14 ($6,963)
  20. 4 Open-market buy Director bought 5,076 shares at $4.16 ($21,116)

Page 2 of 14 · 269 filings